
|Articles|April 1, 2001
- Pharmaceutical Executive-04-01-2001
- Volume 0
- Issue 0
Liberated?
Author(s)Wayne Koberstein
Patents before profits. That soundbite snagged my ears and turned my full attention to the CNN business report. I recognized the voice and the face}Ray Gilmartin, chairman of Merck. Calmly and reasonably, he explained how extraordinary circumstances in the developing world demand that his company uncouple the normally fused objectives of high profitability and unwavering patent protection.
Advertisement
Articles in this issue
almost 25 years ago
Internet DTC - Minding Your P's & Q'salmost 25 years ago
Regulation: Two-Track Planalmost 25 years ago
Policy: Tectonic Shiftalmost 25 years ago
A Matter of Tastealmost 25 years ago
Partnerships: Bargaining Biotechsalmost 25 years ago
Pediatric Mandatealmost 25 years ago
Genentech's Passion for Patientsalmost 25 years ago
Regulation: OK After AllNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement




